#MissKitty #ArtTech The #digital #art #revolution is still #OTW. During the coming #artwalk I'm interspersing with digital art #technology discussion. I am still extraordinarily fascinated. I make stuff that I want to move into.😹 I have a 239 PPI #S11TabUltra to look at my work on. It's the #PPIs.🔦

Zinc & PPIs

Zinc Deficiency Anemia Associated with Proton Pump Inhibition (research article, 2024)
https://doi.org/10.1182/blood-2024-211692

Stomach acid zapped by a single dose of zinc (news article, 2010)
https://medicine.yale.edu/news/medicineatyale/article/stomach-acid-zapped-by-a-single-dose-of/

#health #PPIs #ProtonPumpInhibitors #Zinc #Anemia #gastroenterology #hematology

PPIs: The messengers between organelles in plant cells. 🌿

Shreya Pramanik covers work from Sedaghatmehr & colleagues #MPIMP_Potsdam exploring the lipid composition of chloroplast membranes by developing PPI biosensors giving a readout of their presence. #preprint

#preLight ⬇️ 👀

https://prelights.biologists.com/highlights/new-evidence-for-the-presence-and-function-of-phosphoinositides-ppis-in-the-chloroplast/

#biology #plants #PPIs #signalling #chloroplast #drought #heat

New evidence for the presence and function of phosphoinositides (PPIs) in the chloroplast - preLights

PPIs: The messengers between organelles in plant cells.

preLights

Regular proton pump inhibitor use and incident dementia: population-based cohort study

The finding of this large population-based cohort study indicates that the use of proton pump inhibitors is associated with an increased risk of incident dementia, particularly among APOE ε4 heterozygotes.

https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-022-02478-y

#dementia #PPI #PPIs #APOE #acidreflux #GERD

Regular proton pump inhibitor use and incident dementia: population-based cohort study - BMC Medicine

Background To examine the association between regular use of proton pump inhibitors and the risk of incident dementia, including dementia subtypes, and whether the association differs between APOE genotypes. Methods Based on a prospective analysis of data from the UK Biobank, 501,002 individuals (female, 54.4%) aged between 40 and 70 years, who had no prevalent dementia at baseline, were enrolled between 2006 and 2010 and followed up to 2018. We compared all-cause dementia, Alzheimer’s disease (AD), and vascular dementia (VaD) incidence rates between proton pump inhibitor users and non-users by the Cox proportional hazard model. Results During 4,438,839 person-years of follow-up (median length of follow-up, 9.0 years), there were 2505 incident cases of all-cause dementia, including 932 cases of AD and 524 cases of VaD. The incident rate of all-cause dementia among proton pump inhibitor users was 1.06 events per 1000 person-years, compared with 0.51 events per 1000 person-years among non-users. After adjustment for multiple confounders and indications, the hazard ratios (HRs) of the proton pump inhibitor users were 1.20 (95% CI, 1.07–1.35) for incident all-cause dementia, 1.23 (95% CI, 1.02–1.49) for incident AD, and 1.32 (95% CI, 1.05–1.67) for incident VaD. In addition, the association between proton pump inhibitor use and all-cause dementia differed by APOE genotype (P for interaction = 0.048). Among APOE ε4 heterozygotes, the fully adjusted HR of proton pump inhibitor use was 1.46 (95% CI, 1.22–1.75) and 1.68 (95% CI, 1.36–2.07), especially for individuals aged 65 years and older. Conclusions The finding of this large population-based cohort study indicates that the use of proton pump inhibitors is associated with an increased risk of incident dementia, particularly among APOE ε4 heterozygotes.

BioMed Central